Hyundai Pharmaceutical Co., Ltd. (004310.KS)
KRW 3710.0
(-2.62%)
KRW 3710.0
(-2.62%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 154.04 Billion KRW | -14.97% |
| 2022 | 181.15 Billion KRW | 10.56% |
| 2021 | 163.85 Billion KRW | 4.04% |
| 2020 | 157.5 Billion KRW | 7.57% |
| 2019 | 146.41 Billion KRW | 0.21% |
| 2018 | 146.1 Billion KRW | -5.5% |
| 2017 | 154.61 Billion KRW | 2.7% |
| 2016 | 150.54 Billion KRW | 2.74% |
| 2015 | 146.53 Billion KRW | -0.51% |
| 2014 | 147.29 Billion KRW | 2.71% |
| 2013 | 143.4 Billion KRW | -4.34% |
| 2012 | 149.9 Billion KRW | 13.57% |
| 2011 | 131.99 Billion KRW | 0.77% |
| 2010 | 130.98 Billion KRW | -2.45% |
| 2009 | 134.26 Billion KRW | 2.73% |
| 2008 | 130.7 Billion KRW | 5.24% |
| 2007 | 124.19 Billion KRW | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 156.78 Billion KRW | 1.78% |
| 2024 Q3 | 154.53 Billion KRW | -3.06% |
| 2024 Q2 | 159.41 Billion KRW | 1.67% |
| 2023 Q2 | 164.8 Billion KRW | -8.32% |
| 2023 Q1 | 179.77 Billion KRW | -0.77% |
| 2023 FY | 154.04 Billion KRW | -14.97% |
| 2023 Q4 | 154.04 Billion KRW | -4.46% |
| 2023 Q3 | 161.22 Billion KRW | -2.17% |
| 2022 Q2 | 182.83 Billion KRW | 14.29% |
| 2022 Q3 | 181.28 Billion KRW | -0.85% |
| 2022 FY | 181.15 Billion KRW | 10.56% |
| 2022 Q4 | 181.15 Billion KRW | -0.07% |
| 2022 Q1 | 159.97 Billion KRW | -2.37% |
| 2021 Q2 | 174.73 Billion KRW | 11.69% |
| 2021 Q3 | 174.6 Billion KRW | -0.08% |
| 2021 Q4 | 163.85 Billion KRW | -6.15% |
| 2021 FY | 163.85 Billion KRW | 4.04% |
| 2021 Q1 | 156.45 Billion KRW | -0.67% |
| 2020 Q4 | 157.5 Billion KRW | -0.9% |
| 2020 FY | 157.5 Billion KRW | 7.57% |
| 2020 Q3 | 158.93 Billion KRW | 3.65% |
| 2020 Q2 | 153.33 Billion KRW | 6.17% |
| 2020 Q1 | 144.42 Billion KRW | -1.36% |
| 2019 Q3 | 160.38 Billion KRW | -0.9% |
| 2019 Q1 | 160.39 Billion KRW | 9.78% |
| 2019 Q2 | 161.83 Billion KRW | 0.9% |
| 2019 Q4 | 146.41 Billion KRW | -8.71% |
| 2019 FY | 146.41 Billion KRW | 0.21% |
| 2018 Q1 | 162.39 Billion KRW | 5.03% |
| 2018 FY | 146.1 Billion KRW | -5.5% |
| 2018 Q4 | 146.1 Billion KRW | -9.95% |
| 2018 Q3 | 162.25 Billion KRW | -0.2% |
| 2018 Q2 | 162.59 Billion KRW | 0.12% |
| 2017 Q2 | 156.98 Billion KRW | 5.26% |
| 2017 FY | 154.61 Billion KRW | 2.7% |
| 2017 Q4 | 154.61 Billion KRW | -1.04% |
| 2017 Q3 | 156.24 Billion KRW | -0.47% |
| 2017 Q1 | 149.14 Billion KRW | -0.93% |
| 2016 Q1 | 145.69 Billion KRW | -0.57% |
| 2016 FY | 150.54 Billion KRW | 2.74% |
| 2016 Q3 | 154.15 Billion KRW | 0.11% |
| 2016 Q4 | 150.54 Billion KRW | -2.34% |
| 2016 Q2 | 153.98 Billion KRW | 5.69% |
| 2015 Q3 | 147.05 Billion KRW | -1.5% |
| 2015 Q2 | 149.28 Billion KRW | -0.16% |
| 2015 Q1 | 149.52 Billion KRW | 1.51% |
| 2015 FY | 146.53 Billion KRW | -0.51% |
| 2015 Q4 | 146.53 Billion KRW | -0.35% |
| 2014 FY | 147.29 Billion KRW | 2.71% |
| 2014 Q4 | 147.29 Billion KRW | -0.32% |
| 2014 Q3 | 147.77 Billion KRW | 1.62% |
| 2014 Q1 | 141.44 Billion KRW | -1.37% |
| 2014 Q2 | 145.41 Billion KRW | 2.81% |
| 2013 Q3 | 150.23 Billion KRW | 1.23% |
| 2013 FY | 143.4 Billion KRW | -4.34% |
| 2013 Q4 | 143.4 Billion KRW | -4.55% |
| 2013 Q1 | 148.3 Billion KRW | -1.06% |
| 2013 Q2 | 148.41 Billion KRW | 0.08% |
| 2012 Q4 | 149.9 Billion KRW | 0.0% |
| 2012 Q1 | 149.35 Billion KRW | 13.15% |
| 2012 FY | 149.9 Billion KRW | 13.57% |
| 2011 FY | 131.99 Billion KRW | 0.77% |
| 2011 Q4 | 131.99 Billion KRW | 0.1% |
| 2011 Q3 | 131.86 Billion KRW | -1.39% |
| 2011 Q2 | 133.71 Billion KRW | 1.38% |
| 2011 Q1 | 131.89 Billion KRW | 0.7% |
| 2010 Q4 | 130.98 Billion KRW | -2.97% |
| 2010 Q1 | 134.14 Billion KRW | -0.09% |
| 2010 Q3 | 134.99 Billion KRW | -1.56% |
| 2010 FY | 130.98 Billion KRW | -2.45% |
| 2010 Q2 | 137.14 Billion KRW | 2.23% |
| 2009 Q2 | 137.08 Billion KRW | 8.41% |
| 2009 Q4 | 134.26 Billion KRW | -1.85% |
| 2009 Q3 | 136.79 Billion KRW | -0.21% |
| 2009 Q1 | 126.45 Billion KRW | -3.25% |
| 2009 FY | 134.26 Billion KRW | 2.73% |
| 2008 Q2 | 134.34 Billion KRW | 1.4% |
| 2008 Q3 | 132.25 Billion KRW | -1.55% |
| 2008 Q1 | 132.49 Billion KRW | 6.68% |
| 2008 FY | 130.7 Billion KRW | 5.24% |
| 2008 Q4 | 130.7 Billion KRW | -1.18% |
| 2007 Q2 | 118.35 Billion KRW | 2.64% |
| 2007 Q3 | 123.04 Billion KRW | 3.96% |
| 2007 Q1 | 115.31 Billion KRW | 0.0% |
| 2007 FY | 124.19 Billion KRW | 0.0% |
| 2007 Q4 | 124.19 Billion KRW | 0.94% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 198.21 Billion KRW | 22.285% |
| Dong-A Socio Holdings Co., Ltd. | 1957.1 Billion KRW | 92.129% |
| Ildong Holdings Co., Ltd. | 876.99 Billion KRW | 82.435% |
| HANDOK Inc. | 790.33 Billion KRW | 80.51% |
| Kukje Pharma Co., Ltd. | 170.61 Billion KRW | 9.717% |
| Yuhan Corporation | 2814.07 Billion KRW | 94.526% |
| Dong-A ST Co., Ltd. | 1315.21 Billion KRW | 88.288% |
| SAMSUNG PHARM. Co., LTD. | 93.47 Billion KRW | -64.787% |
| Hanmi Pharm. Co., Ltd. | 1952.03 Billion KRW | 92.109% |
| Hanall Biopharma Co.,Ltd | 239.74 Billion KRW | 35.748% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | 67.149% |
| Dong Sung Bio Pharm.Co.,Ltd. | 114.97 Billion KRW | -33.98% |
| MYUNGMOON Pharm co.,Ltd | 236.54 Billion KRW | 34.88% |
| Hana Pharm Co., Ltd. | 348.38 Billion KRW | 55.784% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | 22.285% |
| Ilsung Pharmaceuticals Co., Ltd. | 419.18 Billion KRW | 63.253% |
| REYON Pharmaceutical Co., Ltd. | 499.77 Billion KRW | 69.178% |
| Aprogen pharmaceuticals,Inc. | 589.39 Billion KRW | 73.865% |
| JW Holdings Corporation | 1176.26 Billion KRW | 86.904% |
| Ildong Pharmaceutical Co., Ltd. | 611.26 Billion KRW | 74.799% |
| Chong Kun Dang Pharmaceutical Corp. | 1402.42 Billion KRW | 89.016% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 76.119% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | 55.999% |
| Samil Pharmaceutical Co.,Ltd | 370.68 Billion KRW | 58.444% |
| Jeil Pharmaceutical Co.,Ltd | 487.32 Billion KRW | 68.391% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | 22.285% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1078.06 Billion KRW | 85.711% |
| Daewoong pharmaceutical Co.,Ltd | 1770.31 Billion KRW | 91.299% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 76.119% |
| Yuhan Corporation | 2814.07 Billion KRW | 94.526% |
| Jeil Pharma Holdings Inc | 879.99 Billion KRW | 82.495% |
| Yungjin Pharm. Co., Ltd. | 226.6 Billion KRW | 32.021% |
| Suheung Co., Ltd. | 993.73 Billion KRW | 84.499% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 76.119% |
| Samjin Pharmaceuticals Co., Ltd. | 419.9 Billion KRW | 63.315% |
| Korea United Pharm Inc. | 468.86 Billion KRW | 67.146% |
| CKD Bio Corp. | 293.78 Billion KRW | 47.567% |
| Daewon Pharmaceutical Co., Ltd. | 507.99 Billion KRW | 69.677% |
| Dongwha Pharm.Co.,Ltd | 564.97 Billion KRW | 72.735% |
| Whan In Pharm Co.,Ltd. | 401.22 Billion KRW | 61.607% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | 55.999% |
| Chong Kun Dang Holdings Corp. | 1456 Billion KRW | 89.42% |
| Boryung Corporation | 922.36 Billion KRW | 83.299% |
| Bukwang Pharmaceutical Co., Ltd. | 442.46 Billion KRW | 65.185% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | 67.149% |
| JW Lifescience Corporation | 255.83 Billion KRW | 39.789% |